Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders
Identifieur interne : 001B25 ( Main/Corpus ); précédent : 001B24; suivant : 001B26Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders
Auteurs : Alisha E. King ; Jim Mintz ; Donald R. RoyallSource :
- Movement Disorders [ 0885-3185 ] ; 2011-06.
English descriptors
- KwdEn :
Abstract
Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of 123I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of 123I‐metaiodobenzylguanidine uptake. 123I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23659
Links to Exploration step
ISTEX:BA725DD8E9CFB2DBBAA45593106662570E43744DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders</title><author><name sortKey="King, Alisha E" sort="King, Alisha E" uniqKey="King A" first="Alisha E." last="King">Alisha E. King</name><affiliation><mods:affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Mintz, Jim" sort="Mintz, Jim" uniqKey="Mintz J" first="Jim" last="Mintz">Jim Mintz</name><affiliation><mods:affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name><affiliation><mods:affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>South Texas Veterans' Health System Audie L. Murphy Division GRECC, San Antonio, Texas, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BA725DD8E9CFB2DBBAA45593106662570E43744D</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23659</idno><idno type="url">https://api.istex.fr/document/BA725DD8E9CFB2DBBAA45593106662570E43744D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001B25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders</title><author><name sortKey="King, Alisha E" sort="King, Alisha E" uniqKey="King A" first="Alisha E." last="King">Alisha E. King</name><affiliation><mods:affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Mintz, Jim" sort="Mintz, Jim" uniqKey="Mintz J" first="Jim" last="Mintz">Jim Mintz</name><affiliation><mods:affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Royall, Donald R" sort="Royall, Donald R" uniqKey="Royall D" first="Donald R." last="Royall">Donald R. Royall</name><affiliation><mods:affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>South Texas Veterans' Health System Audie L. Murphy Division GRECC, San Antonio, Texas, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-06">2011-06</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1218">1218</biblScope><biblScope unit="page" to="1224">1224</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BA725DD8E9CFB2DBBAA45593106662570E43744D</idno><idno type="DOI">10.1002/mds.23659</idno><idno type="ArticleID">MDS23659</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer's disease</term><term>Parkinson's disease</term><term>dementia with Lewy bodies</term><term>multiple system atrophy</term><term>parasomnias</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of 123I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of 123I‐metaiodobenzylguanidine uptake. 123I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Alisha E. King MD</name><affiliations><json:string>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</json:string></affiliations></json:item><json:item><name>Jim Mintz PhD</name><affiliations><json:string>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</json:string></affiliations></json:item><json:item><name>Donald R. Royall MD</name><affiliations><json:string>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</json:string><json:string>Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</json:string><json:string>Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</json:string><json:string>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</json:string><json:string>South Texas Veterans' Health System Audie L. Murphy Division GRECC, San Antonio, Texas, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dementia with Lewy bodies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>multiple system atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Alzheimer's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parasomnias</value></json:item></subject><articleId><json:string>MDS23659</json:string></articleId><language><json:string>eng</json:string></language><abstract>Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of 123I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of 123I‐metaiodobenzylguanidine uptake. 123I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.866</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>2091</abstractCharCount><pdfWordCount>3866</pdfWordCount><pdfCharCount>25264</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>264</abstractWordCount></qualityIndicators><title>Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>1224</last><first>1218</first></pages><issn><json:string>0885-3185</json:string></issn><issue>7</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23659</json:string></doi><id>BA725DD8E9CFB2DBBAA45593106662570E43744D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/BA725DD8E9CFB2DBBAA45593106662570E43744D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/BA725DD8E9CFB2DBBAA45593106662570E43744D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BA725DD8E9CFB2DBBAA45593106662570E43744D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*This study has been supported by the estate of Julia and Van Buren Parr.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders</title><author><persName><forename type="first">Alisha E.</forename><surname>King</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation></author><author><persName><forename type="first">Jim</forename><surname>Mintz</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation></author><author><persName><forename type="first">Donald R.</forename><surname>Royall</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Psychiatry, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284‐7792, USA</p></note><affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><affiliation>Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><affiliation>Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><affiliation>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><affiliation>South Texas Veterans' Health System Audie L. Murphy Division GRECC, San Antonio, Texas, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-06"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1218">1218</biblScope><biblScope unit="page" to="1224">1224</biblScope></imprint></monogr><idno type="istex">BA725DD8E9CFB2DBBAA45593106662570E43744D</idno><idno type="DOI">10.1002/mds.23659</idno><idno type="ArticleID">MDS23659</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of 123I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of 123I‐metaiodobenzylguanidine uptake. 123I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>dementia with Lewy bodies</term></item><item><term>Parkinson's disease</term></item><item><term>multiple system atrophy</term></item><item><term>Alzheimer's disease</term></item><item><term>parasomnias</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-04-15">Received</change><change when="2010-12-20">Registration</change><change when="2011-06">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/BA725DD8E9CFB2DBBAA45593106662570E43744D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mds.v26.7</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2011-06">June 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23659</doi><idGroup><id type="unit" value="MDS23659"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-04-15"></event><event type="manuscriptRevised" date="2010-12-05"></event><event type="manuscriptAccepted" date="2010-12-20"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-15"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-04-07"></event><event type="publishedOnlineFinalForm" date="2011-06-20"></event><event type="firstOnline" date="2011-04-07"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1218</numbering><numbering type="pageLast">1224</numbering></numberingGroup><correspondenceTo>Department of Psychiatry, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284‐7792, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23659.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="31"></count><count type="wordTotal" number="7018"></count></countGroup><titleGroup><title type="main" xml:lang="en">Meta‐analysis of <sup>123</sup>I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders<link href="#fn1"></link><link href="#fn2"></link><link href="#fn3"></link></title><title type="short" xml:lang="en"><sup>123</sup>I‐MIBG Cardiac Uptake and LB Diagnoses</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Alisha E.</givenNames><familyName>King</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jim</givenNames><familyName>Mintz</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2 #af3 #af4 #af5" corresponding="yes"><personName><givenNames>Donald R.</givenNames><familyName>Royall</familyName><degrees>MD</degrees></personName><contactDetails><email>Royall@uthscsa.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>South Texas Veterans' Health System Audie L. Murphy Division GRECC, San Antonio, Texas, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">dementia with Lewy bodies</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">multiple system atrophy</keyword><keyword xml:id="kwd4">Alzheimer's disease</keyword><keyword xml:id="kwd5">parasomnias</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac <sup>123</sup>I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered <sup>123</sup>I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of <sup>123</sup>I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of <sup>123</sup>I‐metaiodobenzylguanidine uptake. <sup>123</sup>I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. <sup>123</sup>I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 <i>Movement</i> Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p></note><note xml:id="fn2"><p>This study has been supported by the estate of Julia and Van Buren Parr.</p></note><note xml:id="fn3"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>123I‐MIBG Cardiac Uptake and LB Diagnoses</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Meta‐analysis of</title></titleInfo><name type="personal"><namePart type="given">Alisha E.</namePart><namePart type="family">King</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jim</namePart><namePart type="family">Mintz</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Donald R.</namePart><namePart type="family">Royall</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><affiliation>Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><affiliation>Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><affiliation>Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA</affiliation><affiliation>South Texas Veterans' Health System Audie L. Murphy Division GRECC, San Antonio, Texas, USA</affiliation><description>Correspondence: Department of Psychiatry, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284‐7792, USA</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-06</dateIssued><dateCaptured encoding="w3cdtf">2010-04-15</dateCaptured><dateValid encoding="w3cdtf">2010-12-20</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">4</extent><extent unit="references">31</extent><extent unit="words">7018</extent></physicalDescription><abstract lang="en">Patients with parkinsonism pose a diagnostic challenge. Parkinson's disease may be difficult to distinguish from multiple system atrophy and progressive supranuclear palsy, whereas Parkinson's disease and dementia with Lewy bodies can be difficult to distinguish from Alzheimer's disease and other dementias. A number of studies have found diminished cardiac 123I‐metaiodobenzylguanidine uptake in Lewy body–related conditions (Parkinson's disease and Lewy body dementia). In 2005, the Dementia With Lewy Bodies Consortium considered 123I‐metaiodobenzylguanidine cardiac scintigraphy a “supportive” diagnostic feature, based on limited evidence. We report a meta‐analysis of the literature and an assessment of the utility of 123I‐metaiodobenzylguanidine for the diagnosis of dementia with Lewy bodies and Parkinson's disease. A search was conducted of articles published between 1950 and June 2010. Forty‐six studies involving neuropsychiatric and movement disorders, comprising 2680 subjects, were included in the analysis. A mixed‐effects regression model was used to analyze the delayed mean heart‐to‐mediastinum ratio of 123I‐metaiodobenzylguanidine uptake. 123I‐metaiodobenzylguanidine cardiac scintigraphy sensitively detected and specifically distinguished 2 diagnostic clusters: (1) Parkinson's disease, dementia with Lewy bodies, and rapid eye movement sleep behavior disorder; and (2) normal controls and patients with Alzheimer's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, and frontotemporal dementia. The area under the receiver operating characteristic curve was 0.987 at a cluster discriminatory heart‐to‐mediastinum ratio threshold of 1.77. This threshold yielded 94% sensitivity and 91% specificity for the discrimination of these diagnostic clusters. 123I‐metaiodobenzylguanidine cardiac scintigraphy can accurately distinguish between 2 movement disorders, Parkinson's disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia with Lewy bodies. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*This study has been supported by the estate of Julia and Van Buren Parr.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>dementia with Lewy bodies</topic><topic>Parkinson's disease</topic><topic>multiple system atrophy</topic><topic>Alzheimer's disease</topic><topic>parasomnias</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>1218</start><end>1224</end><total>7</total></extent></part></relatedItem><identifier type="istex">BA725DD8E9CFB2DBBAA45593106662570E43744D</identifier><identifier type="DOI">10.1002/mds.23659</identifier><identifier type="ArticleID">MDS23659</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001B25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:BA725DD8E9CFB2DBBAA45593106662570E43744D
|texte= Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders
}}
| This area was generated with Dilib version V0.6.23. |  |